Article

Enrollment complete in phase III trial of insert for DME

Atlanta-Enrollment is complete for the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study of a proprietary intravitreal insert with fluocinolone acetonide (Medidur FA) to treat diabetic macular edema (DME), announced Alimera Sciences Inc. and pSivida Ltd.

Atlanta-Enrollment is complete for the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study of a proprietary intravitreal insert with fluocinolone acetonide (Medidur FA) to treat diabetic macular edema (DME), announced Alimera Sciences Inc. and pSivida Ltd. The two companies are jointly developing the vehicle under a collaborative research and development agreement.

“This brings us closer to taking . . . the next generation of retinal drug delivery to market and to our ultimate goal of delivering treatments that enrich patients’ quality of life,” said Dan Myers, chief executive officer of Alimera.

Paul Ashton, PhD, limited managing director of pSivida, said, “We are optimistic that [the insert] will offer a solution to the large market we see for this product.”

The double-masked, randomized, multicenter study will follow more than 900 patients in the United States, Canada, Europe, and India for 3 years. Safety and efficacy will be assessed at 2 years.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.